For instance, AR inhibitors, which can be cardioprotective [99,101], would be predicted to be more effective in Her2-amplified breast cancer responsive to trastuzumab/pertuzumab/lapatinib, while inhibitors of Rlip should be more effective in AU565 that should generate more GS-HNE. This evidence concerns the gene ERBB2 and breast cancer.